Ventyx Biosciences announced that the initial patient has been administered a dose in a Phase 2a study of VTX3232 for individuals with early-stage Parkinson’s disease.

Cytonics Completes Phase 1 Enrollment for Study on CYT-108, a New Protease Inhibitor, in Knee Osteoarthritis Patients.

Sep 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Huonslab Reveals Favorable In Vivo PK Study Outcomes for Trastuzumab/HyDIFFUZETM vs. Commercial rHuPH20 and Trastuzumab Co-formulation.

NextPoint Therapeutics Reveals NPX372, a Novel Drug Targeting B7-H7 in Solid Tumors, as New T Cell Engager.

Medigene Gets U.S. FDA Approval for IND of MDG1015, a Novel Third Gen T Cell Therapy Targeting Various Solid Tumors.

Boehringer Ingelheim reveals intention to progress a promising new therapy for Geographic Atrophy, inspired by favorable Phase I outcomes.

B7-H3 (also known as CD276) is a type I transmembrane glycoprotein and a member of the B7 family.

In a pioneering fixed dose study, weekly insulin efsitora alfa achieves A1C reduction comparable to that of daily insulin.

Crestone, Inc. ("Crestone") announced promising initial results from its Phase 2 clinical trial of CRS3123 in patients with Clostridioides difficile infection (CDI).

Aurinia Pharmaceuticals recently disclosed that the first participant has received the initial dose in a Phase 1a single ascending dose (SAD) clinical trial for AUR200.

Roche's fenebrutinib showed almost total reduction in disease activity and disability advancement for as long as 48 weeks in patients with relapsing multiple sclerosis.